Consistent with this observation, the combination of olmesartan and exenatide has been shown to attenuate the renal NADPH oxidase 4 (Nox4) expression in insulin-resistant Otsuka Long-Evans Tokushima Fatty (OLETF) rats (Rodriguez et al., 2020)
The honest answer is: it depends on your starting body weight, metabolic history, blood sugar regulation, and how your body responds to treatment
PlexusDx's Precision Peptide Genetic Test ($298) maps genetic variants in GIPR, FTO, and MC4Rgenes that directly control hunger signals, satiety, and weight regulation
Cardiovascular benefits of GLP-1 receptor agonists in patients living with obesity or overweight: A meta-analysis of randomized controlled trials
The data are presented as mean standard deviation (SD) unless otherwise specified
Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice